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A B S T R A C T
Objective: Idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of synu-
cleinopathies such as Parkinson’s disease (PD). Positron emission tomography (PET) with 18F-FDG reveals me-
tabolic perturbations, which are scored by spatial covariance analysis. However, the resultant pattern scores do
not capture the spatially heterogeneous trajectories of metabolic changes between individual brain regions.
Assuming metabolic progression occurs as a continuum from the healthy control (HC) condition to iRBD and
then PD, we investigated spatial dynamics of progressively perturbed glucose metabolism in a cross-sectional
study.
Methods: 19 iRBD patients, 38 PD patients and 19 HC subjects underwent 18F-FDG PET. The images were
spatially normalized, scaled to the global mean uptake, and automatically parcellated. We contrasted regional
metabolism by group, and allocated the inferred progression to one of several possible trajectories. We further
investigated the correlations between 18F-FDG uptake and the disease duration in the iRBD and PD groups,
respectively. We also explored relationships between 18F-FDG uptake and the Unified Parkinson’s Disease Rating
Scale motor (UPDRS III) scores in the PD group.
Results: PD patients exhibited more extensive relative hyper- and hypo-metabolism than iRBD patients. We
identified three dynamic metabolic trajectories, cross-sectional hypo- or hypermetabolism, cross-sectionally
unchanged hypo- or hypermetabolism, cross-sectionally late hypo- or hypermetabolism, appearing only in the
contrast of PD with iRBD. No correlation was found between relative 18F-FDG metabolism and disease duration
in the iRBD group. Regional hyper- and hypo-metabolism in the PD patients correlated with disease duration or
clinical UPDRS III scores.
Conclusion: Cerebral metabolism changes heterogeneously in a continuum extending from HC to iRBD and PD
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groups in this preliminary study. The distinctive metabolic trajectories point towards a potential neuroimaging
biomarker for conversion of iRBD to frank PD, which should be amenable to advanced pattern recognition
analysis in future longitudinal studies.
1. Introduction
Idiopathic rapid eye movement (REM) sleep behavior disorder
(iRBD) is a parasomnia characterized by loss of normal skeletal muscle
atonia during REM sleep, leading to potentially harmful dream-enacting
behaviors (Boeve, 2010). There is accumulating evidence that iRBD
occurring in the absence of other clinically established neurological
disorders is a prodromal phase of neurodegenerative synucleinopathies
such as Parkinson’s disease (PD), dementia with Lewy bodies (DLB),
and multiple system atrophy (MSA) (Postuma et al., 2009; Iranzo et al.,
2013; Iranzo et al., 2006). Indeed, meta-analysis shows the incidence of
conversion to neurodegenerative disease is 34% at five years follow-up,
increasing to 82% at 11 years and 97% at 14 years (Galbiati et al.,
2019). Among these disorders, PD is the predominant late sequelus of
iRBD (Iranzo et al., 2013; Schenck et al., 2013), ultimately occurring in
some 43% of iRBD cases (Galbiati et al., 2019). Other studies have
shown that 30–80% of PD patients present RBD symptoms, and that
iRBD may precede the onset of PD motor symptoms by 3–13 years
(Gagnon et al., 2002; Schrag et al., 2015; Iranzo et al., 2005), sug-
gesting a shared or overlapping neurodegenerative pathway.
[18F]-fluorodeoxyglucose (18F-FDG) is widely used as a radiotracer
for positron emission tomography (PET) imaging of cerebral metabo-
lism in vivo; its trapping in brain gives a surrogate index of the meta-
bolic rate for glucose, which is the main carbon source supporting
cerebral energy metabolism. PET with 18F-FDG findings can predict
conversion to Alzheimer s disease (AD) and discriminate AD from other
forms of dementia (Nestor et al., 2018; Drzezga et al., 2018). Similarly,
18F-FDG PET reveals metabolic disturbances in PD (Eidelberg, 1992;
Borghammer et al., 2010; Meles et al., 2017). Given the evident re-
lationship between iRBD and PD, it might follow that 18F-FDG PET
could probe the metabolic patterns common to the two conditions.
Indeed, voxelwise searches reveal regional patterns of altered relative
metabolism in contrasts between controls, iRBD patients, and PD pa-
tients (Ge et al., 2015; Teune et al., 2010; Yong et al., 2007). However,
the process of global intensity normalization raises certain caveats
about the interpretation of such voxelwise comparisons of tracer uptake
(Borghammer et al., 2009).
As an alternative to voxelwise contrasts, spatial covariance analysis
can analyze metabolic patterns, whereby scores of specific disease-re-
lated patterns reflect the cerebral metabolic abnormalities of the par-
ticular neurodegenerative disorders (Eidelberg, 2009; Eckert et al.,
2008; Ma et al., 2007). These scalar values are highly specific in dis-
tinguishing between PD and parkinsonian syndromes, thus aiding their
differential diagnosis, which can be difficult when based only on initial
clinical presentation (Tang et al., 2010). Using spatial covariance ana-
lysis algorithms, our research group has also identified specific RBD-
related covariance pattern (RBDRP) and a PD-related covariance pat-
tern (PDRP) in Chinese cohorts (Ge et al., 2015; Wu et al., 2013), which
resembled the observations of other cohorts (Niethammer and
Eidelberg, 2012). Owing to the unfitness of these spatial covariance
analysis procedures to reveal distinct contributions of particular brain
regions to the final score, a simple pattern score is insensitive to het-
erogeneous (anisotropic) progression of regional metabolic activities.
The conventional method assumes that disease progression is propor-
tional to the pattern vector images arising from the spatial covariance
analysis. If one incorrectly assumes that trajectories of metabolic
changes are linearly progressive in all brain regions, the analysis then
suppresses any present anisotropic changes. Because spurious findings
of consistently isotropic changes may not capture all details of the
disease pathophysiology, we now propose an approach allowing re-
gional differences in the trajectories of metabolic changes in progres-
sion from healthy controls (HC) to iRBD and then PD.
In this cross-sectional study, we mapped 18F-FDG-PET uptake in a
HC group, and in groups of iRBD or PD patients, aiming to explore the
spatially heterogeneous metabolic trajectories occurring during the
transition from HCs to iRBD and clinical PD.
2. Materials and methods
2.1. Participants
Three groups of age- and gender-matched participants were re-
cruited from the Department of Neurology, Huashan Hospital, Fudan
University, China for participation in the protocol, which was approved
by the Research Ethics Committee of Huashan Hospital, Shanghai,
China. All subjects provided written informed consent and took part in
this study voluntarily.
A group of 38 PD patients (24 men; mean age 62.6 ± 7.6 years) was
screened and clinically examined by two neurologists specializing in
movement disorders before their inclusion in the study. PD diagnosis
was according to the United Kingdom Brain Bank criteria (Hughes
et al., 1992): Motor asymmetry, resting tremor, and clear response to
levodopa must be present. Subjects with atypical parkinsonian features
(excessive autonomic symptoms, oculomotor abnormalities) were ex-
cluded. A group of 19 iRBD patients (15 men; mean age
64.9 ± 5.6 years) were recruited, with diagnosis according to the third
edition of the International Classification of Sleep Disorders criteria
(Duchna, 2006; Montplaisir et al., 2010). A sleep disorder specialist
diagnosed these patients based upon their clinical history and poly-
somnography (PSG). A group of 19 HC subjects (15 men; mean age
63.1 ± 7.5 years) were selected from among neurologically normal
subjects undergoing an elective whole-body (including head) cancer-
Table 1
Demographic and clinical profiles of participants.
Variable Healthy controls iRBD PD P
Subjects (number) 19 19 38 —
Sex (male:female) 15:4 15:4 24:14 0.316a
Age (years) 63.1 ± 7.5 64.9 ± 5.6 62.6 ± 7.6 0.512b
Education (years) — 12.6 ± 3.1 18.4 ± 7.6 0.002c
Duration of iRBD symptoms (months) after diagnosis 70.4 ± 43.7
Duration of motor symptoms(months) after diagnosis — 38.5 ± 24.3
UPDRS III score at time of scanning — 2.4 ± 2.1 18.4 ± 7.6 <0.0001c
Demographic and clinical data are presented as mean ± standard deviation.
a Chi-square for gender; b Analysis of variance; c Two-sample t-tests.
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screening scan with 18F-FDG PET. Only subjects without psychiatric
disorder, and without use of psychotropic medication or hormone re-
placement within the prior six months, and without history of neuro-
logical disease, head injury, or alcohol abuse, were included in the HC
group (Zhang et al., 2017). Any cases with occult 18F-FDG-avid carci-
noma on PET/CT examination were excluded. As described previously
(Ge et al., 2015; Wu et al., 20142014), we excluded the possibility of
RBD occurring in the HC groups by their response to the RBD-Single-
Question Screen (RBDSQ) (Postuma et al., 2012). However, according
to the RBDSQ, 21 of 38 (55.3%) PD patients had RBD symptoms, which
is consistent with the relevant literature (Gagnon et al., 2002).
We evaluated motor symptoms of patients with PD and iRBD using
the Unified Parkinson’s Disease Rating Scale subscale (UPDRS III, items
18 to 31), which as administered at least 12 h after the cessation of
antiparkinsonian medications. The clinical and demographic details of
all included subjects are summarized in Table 1. Exclusion criteria for
all participants included: (1) Significant general medical comorbidities,
such as chronic obstructive pulmonary disease; (2) Central nervous
system comorbidities such as cerebrovascular diseases, brain tumors,
stroke, and encephalitis; (3) Metabolic diseases; (4) Primary psychiatric
illnesses; (5) Previous abnormal findings on cranial magnetic resonance
imaging (MRI) or computed tomography (CT); (6) Pregnancy and lac-
tation. In addition, all PD patients and their caregivers were asked
about patients’ cognitive status. There were no amnestic reports of
reduction in quality of life or hallucinations.
2.2. 18F-FDG PET scanning
Before PET scanning, all participants were required to fast for at
least six hours, but had free access to water. The PD patients withheld
their medication for at least 12 h. PET scans were performed with a
Siemens Biograph 64 HD PET/CT (Siemens, Germany) in three-di-
mensional (3D) mode. Emission data was recorded for ten minutes at
60 min after intravenous injection of 185 ± 25 MBq of 18F-FDG (Wu
et al., 2013). In addition, a low-dose CT transmission scan was carried
out for attenuation correction. Data were reconstructed using 3D-or-
dered subset expectation maximization and corrected for random co-
incidences, scatter, and radioactive decay. All studies in the patient and
HC subjects were conducted in a dimly lit room with minimal back-
ground noise.
2.3. Imaging processing
As a preliminary step, DICOM files were exported to a PC and
converted into the Analyze format. Imaging data preprocessing was
performed using Statistical Parametric Mapping (SPM5) software
(Wellcome Department of Imaging Neuroscience, Institute of
Neurology, London, UK) implemented in Matlab 7.2.0 (Mathworks Inc,
Fig. 1. (A) Brain regions with significantly (P < 0.0004) higher (yellow)/lower (blue) relative glucose metabolism in iRBD patients compared with controls. (B)
Brain regions with significantly (P < 0.0004) higher (yellow)/lower (blue) relative glucose metabolism in PD patients compared with controls. (C) Brain regions with
significantly (P < 0.0004) higher (yellow)/lower (blue) relative glucose metabolism in PD patients compared with iRBD patients. (For interpretation of the re-
ferences to color in this figure legend, the reader is referred to the web version of this article.)
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Sherborn, MA, USA). Scans from each subject were spatially normalized
into Montreal Neurological Institute (MNI) space with linear and non-
linear 3D transformations. The spatially normalized PET images were
then smoothed in 3D by a Gaussian filter of 10 mm full-width at half-
maximum to reduce the individual anatomical variations and to in-
crease the signal-to-noise ratio of the voxelwise data. The radioactivity
images were scaled to the global mean activity in a whole brain mask to
report relative regional glucose metabolism (Tang et al., 2010).
2.4. Data analysis
The spatially normalized and intensity-scaled PET images were
aligned to an updated version of the automated anatomical labeling
(AAL) atlas (Tzourio-Mazoyer et al., 2002) (provided by PMOD), par-
cellating the brain into 119 anatomical regions of interest (ROIs, de-
noted as AAL-119). For PD patients, scans from those with pre-
dominantly right-sided symptoms were flipped according to the UPDRS
motor scores so that all hemispheres contralateral to the clinically more
affected limbs appeared on the right side of the brain. For scans from
normal controls and iRBD patients, flips were performed as described
previously (Huang et al., 2019).
2.5. Characterizing metabolic trajectories
Regional relative metabolism was adjusted using the linear regres-
sion method to control the effects of age, gender, and education.
Statistical analysis of relative metabolism in the HC, iRBD, and PD
groups was performed using SPSS software (version 19.0) to search for
patterns of metabolic change characterizing an inferred transition from
the HC to iRBD and then PD. To identify the inferred progressive me-
tabolic changes, we performed one-way analysis of variance (ANOVA)
in conjunction with Bonferroni test to correct for multiple comparisons.
To control the type 1 error, the statistical significance was set as
P < 0.0004(0.05/119). We further investigated the correlations be-
tween 18F-FDG uptake in 119 regions and the disease duration in the
iRBD and PD groups, respectively. Because iRBD patients have no or
very mild motor impairment, we only investigated the correlation
between 18F-FDG uptake and UPDRS III scores in the PD group.
3. Results
3.1. Regional relative metabolic differences between iRBD patients and
healthy controls
Compared with the HC group, iRBD patients exhibited significantly
decreased glucose metabolism in the bilateral calcarine, cuneus, lingual
gyrus and right inferior occipital gyrus (P < 0.0004), and relatively
increased glucose metabolism in bilateral superior frontal gyrus and
right parahippocampal gyrus (P < 0.0004). (Fig. 1A, Supplementary
Materials_1 Table 1).
3.2. Regional metabolic differences between PD patients and HCs
Compared with the HC group, PD patients showed significantly
decreased glucose metabolism in the bilateral calcarine, cuneus, lingual
gyrus, superior occipital gyrus, middle occipital gyrus, inferior occipital
gyrus, right angular gyrus and middle temporal gyrus (P < 0.0004),
and relatively increased glucose metabolism in the bilateral frontal
cortex, olfactory cortex, insula, anterior cingulate gyrus, middle cin-
gulate gyrus, hippocampus, parahippocampal gyrus, amygdala, para-
central lobule, putamen, pallidum, Cerebellum3, left supplementary
motor area, supramarginal gyrus, temporal pole (middle temporal
gyrus), inferior temporal gyrus, Cerebellum45, Cerebellum8, and
Vermis12, Vermis3, pons (P < 0.0004). (Fig. 1B, Supplementary Ma-
terials_1 Table 2).
3.3. Regional metabolic differences between PD patients and iRBD patients
Compared with the iRBD group, PD patients exhibited significantly
decreased glucose metabolism in the bilateral superior occipital gyrus,
right middle occipital gyrus and inferior occipital gyrus (P < 0.0004)
and relatively increased glucose metabolism in the left middle cingulate
gyrus, right olfactory cortex, paracentral lobule and caudate nucleus
(P < 0.0004). (Fig. 1C, Supplementary Materials_1 Table 3).
3.4. Inferred dynamic patterns of altered cerebral glucose metabolism
between the HC, iRBD, and PD groups
In the 119 brain regions, we identified three types of dynamic me-
tabolic pattern across the HC, iRBD, and PD cohorts (Table 2). These
were:
(1) Cross-sectional hyper- or hypometabolism: There was significant
difference between any two groups of HC, iRBD and PD as well as a
consistent trend of metabolic increase or decrease across the three
cohorts. Cross-sectional hypometabolism was present in the right
inferior occipital gyrus (P < 0.0004) (Fig. 2A). None of the 119
brain regions were cross-sectionally hypermetabolic.
(2) Cross-sectionally unchanged hypo- or hypermetabolism: There was
significant difference between HC and iRBD, but no further differ-
ence between iRBD and PD. The cross-sectionally unchanged hy-
pometabolism was found in the bilateral calcarine, cuneus and
lingual gyrus (P < 0.0004) (Fig. 2 B-G). The cross-sectionally un-
changed hypermetabolic regions were found in the bilateral su-
perior frontal gyrus and right parahippocampal gyrus (P < 0.0004)
(Fig. 2 H-J).
(3) Cross-sectionally late hypo- or hypermetabolism: There was sig-
nificant difference between iRBD and PD but no difference between
HC and iRBD. These hypometabolic regions were the bilateral su-
perior occipital gyrus and right middle occipital gyrus (P < 0.0004)
(Fig. 2 K-M). The relatively hypermetabolic regions were left
middle cingulate gyrus, right olfactory cortex and paracentral lo-
bule (P < 0.0004) (Fig. 2 N-P).
Table 2
Three dynamic metabolic patterns and the percentage of regional glucose me-
tabolism of iRBD/PD patients to HCs.
Pattern Labelled
number
Labelled region Percentage of
iRBD to HC (%)
Percentage of PD
to HC (%)
Cross-sectional
Hypometabolism Decrease Decrease
54 Occipital_Inf_R −7.68 ± 5.49 −14.95 ± 3.93
Cross-sectionally unchanged
Hypometabolism Decrease Decrease
43 Calcarine_L −12.62 ± 4.34 −16.61 ± 3.38
44 Calcarine_R −10.53 ± 4.72 −14.94 ± 3.82
45 Cuneus_L −5.10 ± 3.05 −8.69 ± 3.40
46 Cuneus_R −6.43 ± 2.94 −10.16 ± 3.58
47 Lingual_L −7.82 ± 3.62 −10.97 ± 3.23
48 Lingual_R −8.35 ± 4.01 −11.74 ± 3.24
Hypermetabolism Increase Increase
3 Frontal_Sup_L 4.44 ± 2.71 5.27 ± 2.49
4 Frontal_Sup_R 5.43 ± 2.92 4.66 ± 2.02
40 Parahippocampus_R 3.92 ± 2.66 5.84 ± 2.93
Cross-sectionally late
Hypometabolism Decrease Decrease
49 Occipital_Sup_L −3.02 ± 3.41 −7.77 ± 3.53
50 Occipital_Sup_R −3.28 ± 3.35 −8.06 ± 3.72
52 Occipital_Mid_R −3.68 ± 3.52 −9.83 ± 3.62
Hypermetabolism Increase Increase
22 Olfactory_R 3.19 ± 4.38 9.32 ± 5.32
33 Cingulum_Mid_L 3.78 ± 2.67 7.93 ± 3.25
70 Paracentral_Lobule_R 2.95 ± 6.04 10.57 ± 6.40
Vaules are presented as mean ± standard deviation.
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3.5. Correlation of relative metabolic disturbances with disease duration or
UPDRS III scores
No correlation was found between relative 18F-FDG metabolism and
disease duration in iRBD group. In PD group, a slight negative corre-
lation between relative metabolic values and disease duration existed in
the right middle frontal gyrus (r = −0.351, Puncorrected = 0.031), and a
positive correlation existed in the right posterior cingulate gyrus
(r = 0.334, Puncorrected = 0.041). Relative metabolic values correlated
with UPDRS III scores negatively in the right middle temporal gyrus
(r = −0.336, Puncorrected = 0.039), and positively in the bilateral
Cerebellum8 (Left: r = 0.322, Puncorrected = 0.049; Right: r = 0.321,
Puncorrected = 0.049), and Vermis8 (r = 0.383, Puncorrected = 0.018),
Vermis9 (r = 0.339, Puncorrected = 0.037), Vermis10 (r = 0.352,
Puncorrected = 0.030).
4. Discussion
We present in detail a comparison of relative glucose metabolism in
brain regions of a HC group, and in iRBD and PD patient groups.
Assuming a temporal sequence in the progression from a HC state to a
transitional metabolic condition of iRBD and ultimately to PD, we ex-
plored for anisotropic metabolic changes, which might identify the key
regional metabolic features of iRBD patients related to their later
Fig. 2. The three categories of group differences in relative FDG uptake in representative brain regions (P < 0.0004). (A) The cross-sectional hypometabolism was
present in the right inferior occipital gyrus. (B-G) The cross-sectionally unchanged hypometabolism was found in the bilateral calcarine, cuneus and lingual gyrus. (H-
J) The cross-sectionally unchanged hypermetabolism was found in the bilateral superior frontal gyrus and right parahippocampal gyrus. (K-M) These hypometabolic
regions in PD group were the bilateral superior occipital gyrus and right middle occipital gyrus. (N-P) The relatively hypermetabolic regions in PD group were right
olfactory cortex, left middle cingulate gyrus, and right paracentral lobule.
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conversion to PD. Thus, our objective was to identify a metabolic sig-
nature of synucleinopathy that precedes the onset of core motor
symptoms. Our approach differs from earlier representations of disease-
specific metabolic patterns, in that we do not require scalar covariance
of cerebral metabolism in all afflicted regions, but allow anisotropy.
This approach may better accommodate metabolic spatial hetero-
geneity of the disease process.
We find that the iRBD and PD patient groups both demonstrate
extensive hypometabolism in occipital regions, together with relative
hypermetabolism in the frontal regions. In comparison, PD patients had
more widely distributed brain areas with metabolic changes. Among
them, the areas of metabolic reduction involved more occipital lobe
regions and some parts of temporal lobe, while the areas of relatively
high metabolism involve more frontal lobe regions and many other
cerebral or cerebellar regions. Thus, there is a gradual shift towards
decreased metabolic rate in posterior cortical regions. Simultaneously,
relative increased metabolism occurs in frontal and other regions. This
pattern is consistent with previous reports (Ge et al., 2015; Ma et al.,
2007; Wu et al., 20142014; Meles et al., 2018), and suggests a broad
overlap of cerebrometabolic changes in iRBD and PD.
Similarly to the proposed “brain glucose metabolism heterogeneity”
discerned in iRBD patients by a data-driven approach (Arnaldi et al.,
2019), we infer in this cross-sectional study a variety of trajectories of
regional cerebral metabolism in a conjectured transition from the HC
group to iRBD and eventually to PD, which is considered as sui generis
for synucleinopathies. Although there is a lack of difference in most of
the 119 segmented brain regions, we found that some regions showed
one of three change patterns: (1) “cross-sectional” hypo- or hyperme-
tabolism, which means from the HC group to iRBD and finally to the PD
group, there are consistent and continuous changes in brain metabo-
lism. (2) “cross-sectionally unchanged” hypo- or hypermetabolism,
which means brain metabolism changes in the early stage of the disease
(i.e. iRBD) and remains stable in the following course of the disease. Or
(3) “cross-sectionally late” hypo- or hypermetabolism, which means
brain metabolism changes significantly only from iRBD stage to PD
stage. Therefore, “cross-sectionally unchanged” hypo- or hypermeta-
bolism can be regarded as the imaging feature of early diagnosis of PD,
and “cross-sectionally late features” can be regarded as a marker of
phenoconversion. The “cross-sectional” hypo- or hypermetabolism
group show consistent and progressive metabolic changes from HC to
iRBD to PD. We found that in any of the above change patterns, all areas
with decreased glucose metabolism were located in the area of the
occipital lobe mainly responsible for processing of visual information.
Previous studies in iRBD and clinically diagnosed PD have stressed the
importance of posterior cortical dysfunction to various non-motor
symptoms such as visual hallucinations, cognitive impairment and
poorer performance in the color discrimination test (Vendette et al.,
2012; Mentis et al., 2002; Colloby et al., 2002; Vendette et al., 2011).
Furthermore, a longitudinal SPECT study showed that the progression
of regional cerebral blood flow deterioration in the parietal-temporal-
occipital areas could reflect advancing neurodegeneration in iRBD pa-
tients, despite lack of worsening of non-motor impairments (Sakurai
et al., 2014). Another follow-up [18F]-FDG-PET study suggested that
reduced baseline metabolism in the parietal-temporal-occipital areas in
patients with probable RBD might predict eventual phenoconversion to
DLB (Ota et al., 2016). We found that the “cross-sectionally unchanged”
hypometabolism located in the medial parts of occipital lobe, such as
the bilateral calcarine, cuneus and lingual gyrus is predictive of the
development of synucleinopathies such as PD. However, the “cross-
sectional” and “cross-sectionally late” hypometabolism located in the
lateral parts of occipital lobe is indicative of progressive neurodegen-
eration. Our ongoing longitudinal studies in the iRBD patients could
confirm the value of occipital hypometabolism as an imaging marker
for diagnosis and progression assessment of PD or other synucleino-
pathies in their early stages.
We also found some areas with relatively increased glucose
metabolism, which may be due to global normalization under the
premise of absolute metabolism decline of cerebral cortex18, although
this concept has been debated (Ma et al., 2009; Borghammer et al.,
2009). However, these changes still could be regarded as preclinical
signs or progression indicators of synucleinopathies.
Our ROI analysis indicated no correlation between relative glucose
metabolism in certain brain regions and disease duration or UPDRS III
scores in iRBD patients and weak correlations in PD patients. The re-
sults are not surprising considering that the patients with iRBD have no
parkinsonian motor signs and the time courses differ greatly for dif-
ferent patients developing from iRBD to PD. For PD patients, the ne-
gative correlation between disease duration and metabolism in the
middle frontal gyrus may reflect the deterioration of the frontal func-
tion which is the main feature of the cognition of PD. In contrast, the
posterior cingulate gyrus is mainly related to the cognitive function of
AD and its metabolism may be relatively preserved in PD patients. The
weak correlations between UPDRS motor scores and the cortical me-
tabolism may be due to the fact that the cortical metabolism is more
related to cognitive impairment but not to motor function.
This study was constrained by several limitations in addition to the
relatively small sample size and the lack of longitudinal data which
makes it possible to investigate the value of regional metabolic changes
for predicting the clinical outcomes of RBD at single-subject level.
Firstly, although this study used a ROI-and voxel-based analysis, the
true pattern analyses (e.g., principal component analysis (PCA)) or
cluster analyses were not presented. It still needs to investigate whether
the pattern from PCA or cluster analyses were also efficient in our cases
in the future. Secondly, while all PD patients and their caregivers were
asked about patients’ cognitive status, with no reports of cognitive
decline which constrained their daily life, or the presence of halluci-
nations, no formal neuropsychological testing was undertaken for the
PD group. Ideally, such information would be available. Future studies
should consider possible relationships between metabolic patterns and
cognition. However, cognitive assessments were available for all the
RBD patients in this study (baseline and follow-up assessments). The
follow-up assessments were done after PET examination and no clear
cognitive impairments were found. Due to the diverse time points of the
cognitive tests, we did not include the neuropsychological test data in
the analysis. Future studies should encompass comprehensive cognitive
testing in new studies in order to genuinely eliminate the possibility of
MCI, and should also consider possible relationships between metabolic
patterns and cognition. Thirdly, our HC participants were recruited
without undergoing polysomnography, with exclusion of iRBD only
through Single-Question screening. Although this screening has high
sensitivity and specificity in diagnosing RBD (Postuma et al., 2012), we
concede that screening of controls should properly have entailed a
clinical confirmation. Fourthly, no partial volume correction (PVC) was
not conducted in our study due to the lack of MRI data, which might
hamper the results. Fifthly, we did not calculate the prodromal PD
likehood ratio in this study because we did not have detailed clinical
data of the iRBD patients, such as olfactory function scores. This will be
addressed by ongoing studies. Sixthly, this study is not based on pattern
analyses or cluster analyses. Instead, we did group-wise analysis be-
tween HC, iRBD and PD for the parcellated anatomical ROIs, and tried
to explore the regional metabolic differences in a consecutive or pro-
gressive way, thus explorating of the spatially heterogeneous metabolic
trajectories occurring during the transition from HCs to iRBD and
clinical PD. Finally, the focus of this study was the relationship between
iRBD and PD, which we take to be sui generis for synucleinopathy.
Nevertheless, we are cognizant of the fact that iRBD can convert to
other synucleinopathies such as dementia with Lewy bodies (DLB) and
multiple system atrophy. These conditions should be included any fu-
ture studies with long-term follow-up and a larger sample size.
In conclusion, this 18F-FDG PET study using ROI-and voxel-based
analysis replicates earlier findings of relative cerebral metabolic
anomalies in a relatively limited sample of patients with iRBD and PD.
X. Han, et al. NeuroImage: Clinical 27 (2020) 102294
6
The considerable spatial overlap of relative hypermetabolism in frontal
regions and hypometabolism in posterior occipital regions in both of
our clinical groups suggests a common neurobiological process.
Importantly, we characterized three spatially heterogeneous metabolic
patterns from HC to iRBD and finally to PD, which might act as the
early imaging feature or progression marker of the neurodegeneration
process of PD. These preliminary findings are congruent with our hy-
pothesis of an evolving anisotropically abnormal metabolic network
proceeding from an early iRBD phase to later PD (Wu et al., 2014).
Encouraged by these results, we are now undertaking longitudinal 18F-
FDG PET studies in larger cohorts, and will use advanced pattern re-
cognition algorithms to confirm that the present markers can indeed
predict and monitor the neurodegenerative progression of iRBD to-
wards PD or other synucleinopathies.
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